This invention generally relates to a design and method for developing novel anti-tumor and/or anti-cancer drugs, vaccines and therapies, using microRNA and/or its shRNA homologues/mimics/derivatives. More specifically, the present invention relates to a use of a prokaryote-produced miRNA precursor (pro-miRNA) composition capable of being delivered into human cells and processed by the cells into mature miRNA effectors to elicit specific silencing effects on mir-302-targeted genes, subsequently leading to a beneficial result of tumor suppression and cancer therapy. The prokaryotic cells do not naturally express or process eukaryotic miRNA precursors (pre-miRNA) meanwhile, the present invention also teaches an inducible method for expressing pre-miRNAs, particularly mir-302 precursors by using the prokaryotic transcription system. Since mir-302 is a known tumor suppressor in human, this novel finding advances the design and method for developing new anti-cancer drugs, vaccines and/or therapies directed against multiple kinds of human tumors and cancers.本發明一般而言係關於一種使用微型核糖核酸(microRNA、miRNA)及/或其小髮夾型核糖核酸(shRNA)同源物/類似物/衍生物,發展新穎的抗腫瘤及/或抗癌藥物、疫苗與治療的設計及方法。具體而言,本發明係關於使用原核細胞生產之microRNA前驅物(pro-miRNA)組成物。該組成物被傳送至人類細胞、經處理為成熟的miRNA效應子,並對於能為mir-302標的的基因引發特定靜默效應,接著產生有益腫瘤抑制及癌症治療的結果。原核細胞在自然情況下不表現或處理真核miRNA前驅物(pre-miRNA)。本發明亦教示一種使用原核轉錄系統表現pre-miRNAs,特別是mir-302前驅物的可誘導式方法。由於mir-302對於人類是一腫瘤抑制子,此新穎發現促進了新抗癌藥物、疫苗及/或針對各種人類腫瘤與癌症之治療在設計及方法上的發展。
